In a first, researchers were able to use a genetically modified specific lytic phage strain to stop an otherwise generally lethal drug-resistant Mycobacterium abscessus infection in a cystic fibrosis patient after persistent infections, as reported in the May 8, 2019, issue of Nature Medicine.